1. Home
  2. FINV vs SUPN Comparison

FINV vs SUPN Comparison

Compare FINV & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FINV
  • SUPN
  • Stock Information
  • Founded
  • FINV 2007
  • SUPN 2005
  • Country
  • FINV China
  • SUPN United States
  • Employees
  • FINV N/A
  • SUPN N/A
  • Industry
  • FINV Finance: Consumer Services
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FINV Finance
  • SUPN Health Care
  • Exchange
  • FINV Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • FINV 1.8B
  • SUPN 2.1B
  • IPO Year
  • FINV N/A
  • SUPN 2012
  • Fundamental
  • Price
  • FINV $7.02
  • SUPN $37.74
  • Analyst Decision
  • FINV
  • SUPN Hold
  • Analyst Count
  • FINV 0
  • SUPN 1
  • Target Price
  • FINV N/A
  • SUPN $36.00
  • AVG Volume (30 Days)
  • FINV 557.3K
  • SUPN 376.5K
  • Earning Date
  • FINV 11-18-2024
  • SUPN 02-25-2025
  • Dividend Yield
  • FINV 3.38%
  • SUPN N/A
  • EPS Growth
  • FINV N/A
  • SUPN 130.79
  • EPS
  • FINV 1.19
  • SUPN 1.07
  • Revenue
  • FINV $1,837,029,436.00
  • SUPN $651,972,000.00
  • Revenue This Year
  • FINV $6.61
  • SUPN $7.82
  • Revenue Next Year
  • FINV $7.97
  • SUPN N/A
  • P/E Ratio
  • FINV $5.90
  • SUPN $35.28
  • Revenue Growth
  • FINV 2.92
  • SUPN 6.79
  • 52 Week Low
  • FINV $4.45
  • SUPN $25.53
  • 52 Week High
  • FINV $7.29
  • SUPN $39.37
  • Technical
  • Relative Strength Index (RSI)
  • FINV 59.83
  • SUPN 57.78
  • Support Level
  • FINV $6.91
  • SUPN $36.48
  • Resistance Level
  • FINV $7.12
  • SUPN $38.68
  • Average True Range (ATR)
  • FINV 0.20
  • SUPN 1.06
  • MACD
  • FINV 0.01
  • SUPN 0.09
  • Stochastic Oscillator
  • FINV 84.33
  • SUPN 68.46

About FINV FinVolution Group

FinVolution Group is a provider of online consumer finance in China. It offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers Tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company provides investors with an opportunity to invest in emerging asset class-consumer loans through a variety of investment options. It generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC and its revenues are derived from within the PRC.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: